Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$88 Mln
Revenue (TTM)
$149 Mln
Net Profit (TTM)
$0 Mln
ROE
-1.3 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
4.5
Industry P/E
--
EV/EBITDA
-2
Div. Yield
0 %
Debt to Equity
4
Book Value
$0.3
EPS
$-0.6
Face value
--
Shares outstanding
69,276,593
CFO
$-189.91 Mln
EBITDA
$-172.19 Mln
Net Profit
$-222.97 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Neuronetics (STIM)
| 10.1 | 13.4 | 10.1 | -59.8 | -19.5 | -34.4 | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Neuronetics (STIM)
| -14.3 | -44.2 | -57.8 | 54.0 | -59.9 | 147.4 | -76.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Neuronetics (STIM)
|
1.5 | 88.0 | 149.2 | -39.0 | -21.1 | -155.7 | -- | 4.5 |
| 7.9 | 5,388.2 | 6,552.2 | -530.2 | -4.1 | -9.2 | -- | 0.9 | |
| 278.3 | 7,510.1 | 2,583.2 | 759.9 | 25.2 | 10.8 | 10 | 1.0 | |
| 36.8 | 5,222.6 | 3,436.5 | -8.6 | 2.2 | -0.4 | -- | 2.1 | |
| 112.8 | 6,549.6 | 507.4 | -187.7 | -36.2 | -26.4 | -- | 10.0 | |
| 76.1 | 4,758.4 | 1,541.6 | 233.6 | 21.6 | 21.4 | 21.4 | 4.5 | |
| 178.6 | 9,411.8 | 1,526.9 | -151.5 | 20.0 | -17.1 | -- | 12.9 | |
| 330.4 | 12,964.3 | 1,403.7 | 177.7 | 14.7 | 13.8 | 72.9 | 9.0 | |
| 117.8 | 6,280.4 | 738.3 | 48.9 | 11.4 | 2.4 | 129.6 | 3.0 | |
| 32.1 | 13,716.9 | 6,178.4 | 626.5 | 13.0 | 11.9 | 22.5 | 2.6 |
Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based... treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania. Address: 3222 Phoenixville Pike, Malvern, PA, United States, 19355 Read more
President, CEO & Director
Mr. Keith J. Sullivan
President, CEO & Director
Mr. Keith J. Sullivan
Headquarters
Malvern, PA
Website
The share price of Neuronetics Inc (STIM) is $1.52 (NASDAQ) as of 02-Apr-2026 19:58 EDT. Neuronetics Inc (STIM) has given a return of -19.47% in the last 3 years.
Since, TTM earnings of Neuronetics Inc (STIM) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-2.34
|
4.07
|
|
2024
|
-1.18
|
1.86
|
|
2023
|
-2.79
|
2.46
|
|
2022
|
-4.99
|
3.25
|
|
2021
|
-3.57
|
1.31
|
The 52-week high and low of Neuronetics Inc (STIM) are Rs 4.85 and Rs 0.80 as of 04-Apr-2026.
Neuronetics Inc (STIM) has a market capitalisation of $ 88 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Neuronetics Inc (STIM), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.